A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Recruiting

Phase 1

Phase 2

CRB-701A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Sponsor:

Corbus Pharmaceuticals Inc.

Code:

NCT06265727

Conditions

Solid Tumor, Adult

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CRB-701

Anti-PD-1

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-16. This information was provided to ClinicalTrials.gov by Corbus Pharmaceuticals Inc. on 2025-06-03.